| pubmed-article:18403141 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18403141 | lifeskim:mentions | umls-concept:C0038179 | lld:lifeskim |
| pubmed-article:18403141 | lifeskim:mentions | umls-concept:C0002732 | lld:lifeskim |
| pubmed-article:18403141 | lifeskim:mentions | umls-concept:C0233820 | lld:lifeskim |
| pubmed-article:18403141 | lifeskim:mentions | umls-concept:C0920330 | lld:lifeskim |
| pubmed-article:18403141 | lifeskim:mentions | umls-concept:C0015237 | lld:lifeskim |
| pubmed-article:18403141 | lifeskim:mentions | umls-concept:C0678594 | lld:lifeskim |
| pubmed-article:18403141 | lifeskim:mentions | umls-concept:C0524527 | lld:lifeskim |
| pubmed-article:18403141 | pubmed:issue | 1-2 | lld:pubmed |
| pubmed-article:18403141 | pubmed:dateCreated | 2008-4-29 | lld:pubmed |
| pubmed-article:18403141 | pubmed:abstractText | Carboxymethyl high amylose starch (CM-HAS) and succinate high amylose starch (S-HAS) were proposed as pharmaceutical excipients for oral drug delivery, providing a significant gastroprotection to dosage forms of pancreatic enzymes (alpha-amylase, lipase and trypsin) compared to unprotected enzymes. In acidic medium, carboxylic groups are protonated (at least in tablet surface) ensuring local buffering properties and giving a compact shape of the tablets. The enzymes were formulated individually or in association as three enzymes formulation. After the first hour of incubation (over a 2h experiment) in simulated gastric fluid (SGF), the three pancreatic enzymes retained an overall (average of the three enzymes) activity of 72% when formulated as tablets with CM-HAS excipient and 77% when formulated with S-HAS excipient. Furthermore, after incubation in SGF, the delivery of 75% of the total remaining enzymatic activity in the simulated intestinal fluid (SIF) taken 180 and 170 min for CM-HAS and S-HAS, respectively. Both formulations with carboxylated starch as excipient have a high loading capacity (up to 70-80% enzymes), which is of interest for pancreatic enzymes replacement therapy of pancreatitis. An advantage of these formulations is that gastroprotection is afforded by the carboxylated matrices (carboxylic groups), without enteric coating. | lld:pubmed |
| pubmed-article:18403141 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18403141 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18403141 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18403141 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18403141 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18403141 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18403141 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18403141 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18403141 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18403141 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18403141 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18403141 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18403141 | pubmed:month | May | lld:pubmed |
| pubmed-article:18403141 | pubmed:issn | 0378-5173 | lld:pubmed |
| pubmed-article:18403141 | pubmed:author | pubmed-author:MateescuMirce... | lld:pubmed |
| pubmed-article:18403141 | pubmed:author | pubmed-author:MassicotteLou... | lld:pubmed |
| pubmed-article:18403141 | pubmed:author | pubmed-author:BailleWilms... | lld:pubmed |
| pubmed-article:18403141 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18403141 | pubmed:day | 22 | lld:pubmed |
| pubmed-article:18403141 | pubmed:volume | 356 | lld:pubmed |
| pubmed-article:18403141 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18403141 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18403141 | pubmed:pagination | 212-23 | lld:pubmed |
| pubmed-article:18403141 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:18403141 | pubmed:meshHeading | pubmed-meshheading:18403141... | lld:pubmed |
| pubmed-article:18403141 | pubmed:meshHeading | pubmed-meshheading:18403141... | lld:pubmed |
| pubmed-article:18403141 | pubmed:meshHeading | pubmed-meshheading:18403141... | lld:pubmed |
| pubmed-article:18403141 | pubmed:meshHeading | pubmed-meshheading:18403141... | lld:pubmed |
| pubmed-article:18403141 | pubmed:meshHeading | pubmed-meshheading:18403141... | lld:pubmed |
| pubmed-article:18403141 | pubmed:meshHeading | pubmed-meshheading:18403141... | lld:pubmed |
| pubmed-article:18403141 | pubmed:meshHeading | pubmed-meshheading:18403141... | lld:pubmed |
| pubmed-article:18403141 | pubmed:meshHeading | pubmed-meshheading:18403141... | lld:pubmed |
| pubmed-article:18403141 | pubmed:meshHeading | pubmed-meshheading:18403141... | lld:pubmed |
| pubmed-article:18403141 | pubmed:meshHeading | pubmed-meshheading:18403141... | lld:pubmed |
| pubmed-article:18403141 | pubmed:meshHeading | pubmed-meshheading:18403141... | lld:pubmed |
| pubmed-article:18403141 | pubmed:meshHeading | pubmed-meshheading:18403141... | lld:pubmed |
| pubmed-article:18403141 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18403141 | pubmed:articleTitle | Carboxylated high amylose starch as pharmaceutical excipients. Structural insights and formulation of pancreatic enzymes. | lld:pubmed |
| pubmed-article:18403141 | pubmed:affiliation | Department of Chemistry and Centre BioMed, Université du Québec à Montréal, CP 8888, Succursale A, Montreal, Quebec H3C 3P8 Canada. | lld:pubmed |
| pubmed-article:18403141 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18403141 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18403141 | lld:pubmed |
